Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CytomX Therapeutics, Inc.CTMX · Entity 5124 | Director · CEO | March 17, 2026 | March 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CytomX Therapeutics, Inc.
Report date March 17, 2026 · Filed March 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,078,922 |
Reported balance
After 2026-03-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-17 · Sale · Disposed 118,969 · Balance 1,078,922 F1: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F2: Includes 457,500 RSUs. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 93,158 |
Reported balance
Holding disclosure · report date 2026-03-17 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 93,158 F3: Shares held by Sean A. McCarthy 2018 Trust, of which Reporting Person is trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs").
F2: Includes 457,500 RSUs.
F3: Shares held by Sean A. McCarthy 2018 Trust, of which Reporting Person is trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2018 Filed Mar 5, 2018 21:55 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 62 | $0.95 | $58.59 |
DisclosureSEC source: 0001140361-18-012008 · doc1.xml · nonDerivative · entry 3 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,221 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:55 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 9,000 | $1.13 | $10,205.10 |
DisclosureSEC source: 0001140361-18-012008 · doc1.xml · nonDerivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,159 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:55 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 10,516 | $1.57 | $16,561.65 |
DisclosureSEC source: 0001140361-18-012008 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,159 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 19:53 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $25.82 | $0.00 |
DisclosureSEC source: 0001140361-18-003373 · doc1.xml · derivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2028-01-23 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 1, 2018 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| January 05, 2018 Filed Jan 9, 2018 16:20 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (right to buy) · Derivative | 6,526 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001140361-18-001360 · doc1.xml · derivative · entry 4 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,143 Underlying: Common Stock · 6,526 shares Expires 2021-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| January 05, 2018 Filed Jan 9, 2018 16:20 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 6,526 | $25.01 | $163,215.26 |
DisclosureSEC source: 0001140361-18-001360 · doc1.xml · nonDerivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,643 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.17, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| January 05, 2018 Filed Jan 9, 2018 16:20 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 6,526 | $1.13 | $7,399.83 |
DisclosureSEC source: 0001140361-18-001360 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,169 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 17:25 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (right to buy) · Derivative | 13,052 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001140361-18-000712 · doc1.xml · derivative · entry 4 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,669 Underlying: Common Stock · 13,052 shares Expires 2021-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 17:25 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 13,052 | $21.04 | $274,614.08 |
DisclosureSEC source: 0001140361-18-000712 · doc1.xml · nonDerivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,643 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $20.69 to $21.49, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 17:25 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 13,052 | $1.13 | $14,799.66 |
DisclosureSEC source: 0001140361-18-000712 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 17:55 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (right to buy) · Derivative | 10,240 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001140361-17-045017 · doc1.xml · derivative · entry 7 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,721 Underlying: Common Stock · 10,240 shares Expires 2021-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 17:55 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (right to buy) · Derivative | 4,100 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001140361-17-045017 · doc1.xml · derivative · entry 6 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,193 Underlying: Common Stock · 4,100 shares Expires 2023-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 17:55 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 14,340 | $20.60 | $295,404.00 |
DisclosureSEC source: 0001140361-17-045017 · doc1.xml · nonDerivative · entry 4 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,643 F2 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $20.42 to $20.78, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 17:55 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 10,240 | $1.13 | $11,611.14 |
DisclosureSEC source: 0001140361-17-045017 · doc1.xml · nonDerivative · entry 3 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,983 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 17:55 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 4,100 | $0.95 | $3,874.50 |
DisclosureSEC source: 0001140361-17-045017 · doc1.xml · nonDerivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 30, 2017 Filed Dec 5, 2017 17:55 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantCommon Stock | 398 | $12.15 | $4,834.31 |
DisclosureSEC source: 0001140361-17-045017 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,643 F1 · kind: 398 shares were acquired pursuant to the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 20:34 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (right to buy) · Derivative | 14,342 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001140361-17-040976 · doc1.xml · derivative · entry 4 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,293 Underlying: Common Stock · 14,342 shares Expires 2023-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 20:34 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 14,342 | $19.86 | $284,832.12 |
DisclosureSEC source: 0001140361-17-040976 · doc1.xml · nonDerivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,245 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $19.61 to $20.22, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 20:34 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 14,342 | $0.95 | $13,553.19 |
DisclosureSEC source: 0001140361-17-040976 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,587 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 04, 2017 Filed Oct 6, 2017 22:37 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock · Derivative | 19,120 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001140361-17-037828 · doc1.xml · derivative · entry 4 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,635 Underlying: Common Stock · 19,120 shares Expires 2023-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. F5 · balance_after: Previous Form 4s filed by the Reporting Person included an error in the number of securities beneficially owned by the Reporting Person in Table II, Box 9. The number of derivative securities beneficially owned as reported in Table II, Box 9 of this Form 4 has been adjusted to correct the previous errors and reflects the current number of derivative securities beneficially owned as of this filing date. Read SEC document |
| October 04, 2017 Filed Oct 6, 2017 22:37 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 19,120 | $24.13 | $461,365.60 |
DisclosureSEC source: 0001140361-17-037828 · doc1.xml · nonDerivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,245 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.51 to $24.39, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| October 04, 2017 Filed Oct 6, 2017 22:37 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 19,120 | $0.95 | $18,068.40 |
DisclosureSEC source: 0001140361-17-037828 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,365 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 23:56 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (right to buy) · Derivative | 9,562 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001140361-17-037691 · doc1.xml · derivative · entry 4 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,481 Underlying: Common Stock · 9,562 shares Expires 2023-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 23:56 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 9,562 | $18.57 | $177,566.34 |
DisclosureSEC source: 0001140361-17-037691 · doc1.xml · nonDerivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,245 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.10 to $18.97, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 23:56 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 9,562 | $0.95 | $9,036.09 |
DisclosureSEC source: 0001140361-17-037691 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,807 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2017 Filed Feb 12, 2018 23:00 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GiftCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-006690 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 154,237 F1 · ownership.nature: Held in McCarthy Family Trust dated August 9, 2001, Sean A. McCarthy and Jeanette J. McCarthy, Trustees. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 22:17 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (right to buy) · Derivative | 9,930 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001140361-17-034348 · doc1.xml · derivative · entry 4 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,043 Underlying: Common Stock · 9,930 shares Expires 2023-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 22:17 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 9,930 | $17.32 | $171,987.60 |
DisclosureSEC source: 0001140361-17-034348 · doc1.xml · nonDerivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,245 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $17.01 to $17.50, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 22:17 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 9,930 | $0.95 | $9,383.85 |
DisclosureSEC source: 0001140361-17-034348 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2017 Filed Sep 22, 2017 18:59 UTC Amendment | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (right to buy) · Derivative | 9,930 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001140361-17-036202 · doc1.xml · derivative · entry 5 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,043 Underlying: Common Stock · 9,930 shares Expires 2023-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| September 01, 2017 Filed Sep 22, 2017 18:59 UTC Amendment | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 368 | $17.50 | $6,440.00 |
DisclosureSEC source: 0001140361-17-036202 · doc1.xml · nonDerivative · entry 3 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,245 Read SEC document |
| September 01, 2017 Filed Sep 22, 2017 18:59 UTC Amendment | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 9,562 | $17.32 | $165,613.84 |
DisclosureSEC source: 0001140361-17-036202 · doc1.xml · nonDerivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,613 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $17.01 to $17.50, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 01, 2017 Filed Sep 22, 2017 18:59 UTC Amendment | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 9,930 | $0.95 | $9,383.85 |
DisclosureSEC source: 0001140361-17-036202 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 20:28 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (right to buy) · Derivative | 18,756 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001140361-17-034164 · doc1.xml · derivative · entry 5 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,973 Underlying: Common Stock · 18,756 shares Expires 2023-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 20:28 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 3,000 | $17.51 | $52,530.00 |
DisclosureSEC source: 0001140361-17-034164 · doc1.xml · nonDerivative · entry 3 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,245 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 20:28 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 15,756 | $17.50 | $275,730.00 |
DisclosureSEC source: 0001140361-17-034164 · doc1.xml · nonDerivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,245 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 20:28 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 18,756 | $0.95 | $17,724.42 |
DisclosureSEC source: 0001140361-17-034164 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 22, 2017 18:58 UTC Amendment | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (right to buy) · Derivative | 18,756 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001140361-17-036201 · doc1.xml · derivative · entry 6 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,973 Underlying: Common Stock · 18,756 shares Expires 2023-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| August 31, 2017 Filed Sep 22, 2017 18:58 UTC Amendment | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 9,194 | $17.50 | $160,895.00 |
DisclosureSEC source: 0001140361-17-036201 · doc1.xml · nonDerivative · entry 4 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,245 Read SEC document |
| August 31, 2017 Filed Sep 22, 2017 18:58 UTC Amendment | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 3,000 | $17.51 | $52,530.00 |
DisclosureSEC source: 0001140361-17-036201 · doc1.xml · nonDerivative · entry 3 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,439 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| August 31, 2017 Filed Sep 22, 2017 18:58 UTC Amendment | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 6,562 | $17.50 | $114,835.00 |
DisclosureSEC source: 0001140361-17-036201 · doc1.xml · nonDerivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,439 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| August 31, 2017 Filed Sep 22, 2017 18:58 UTC Amendment | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 18,756 | $0.95 | $17,724.42 |
DisclosureSEC source: 0001140361-17-036201 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 16:50 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (right to buy) · Derivative | 4,781 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001140361-17-031315 · doc1.xml · derivative · entry 4 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,729 Underlying: Common Stock · 4,781 shares Expires 2023-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 16:50 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 4,781 | $15.00 | $71,715.00 |
DisclosureSEC source: 0001140361-17-031315 · doc1.xml · nonDerivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,245 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 16:50 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 4,781 | $0.95 | $4,518.05 |
DisclosureSEC source: 0001140361-17-031315 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,026 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 03, 2017 Filed Jul 6, 2017 15:20 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (right to buy) · Derivative | 4,781 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001140361-17-027296 · doc1.xml · derivative · entry 4 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,510 Underlying: Common Stock · 4,781 shares Expires 2023-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| July 03, 2017 Filed Jul 6, 2017 15:20 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 4,781 | $15.52 | $74,201.12 |
DisclosureSEC source: 0001140361-17-027296 · doc1.xml · nonDerivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,245 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.34 to $15.70, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| July 03, 2017 Filed Jul 6, 2017 15:20 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 4,781 | $0.95 | $4,518.05 |
DisclosureSEC source: 0001140361-17-027296 · doc1.xml · nonDerivative · entry 1 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,026 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 26, 2017 Filed Jun 27, 2017 20:55 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (right to buy) · Derivative | 4,481 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001140361-17-026273 · doc1.xml · derivative · entry 4 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,291 Underlying: Common Stock · 4,481 shares Expires 2023-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| June 26, 2017 Filed Jun 27, 2017 20:55 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 4,481 | $15.00 | $67,215.00 |
DisclosureSEC source: 0001140361-17-026273 · doc1.xml · nonDerivative · entry 2 McCarthy Sean A. · CIK 0001654058 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,245 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.